PSO

PSO Other Current Assets

£834.93MQuarterly · GBP

Period ending:

PSO FY Other Current AssetsGBP
PSO FY Other Current Assets1985-12-31: £0.001986-12-31: £0.001987-12-31: £0.001988-12-31: £0.001989-12-31: £0.001990-12-31: £0.001991-12-31: £24.50M1992-12-31: £42.90M1993-12-31: £35.50M1994-12-31: £43.50M1995-12-31: £61.20M1996-12-31: £53.50M1997-12-31: £807.00M1998-12-31: £1.13B1999-12-31: £1.13B2000-12-31: £12.05M2001-12-31: £1.28B2002-12-31: £1.23B2003-12-31: £1.28B2004-12-31: £1.27B2005-12-31: £1.46B2006-12-31: £1.36B2007-12-31: £1.51B2008-12-31: £868.00M2009-12-31: £824.00M2010-12-31: £835.00M2011-12-31: £847.00M2012-12-31: £1.94B2013-12-31: £1.26B2014-12-31: £1.19B2015-12-31: £1.22B2016-12-31: £1.42B2017-12-31: £1.87B2018-12-31: £1.77B2019-12-31: £1.43B2020-12-31: £1.29B2021-12-31: £1.30B2022-12-31: £1.30B2023-12-31: £1.20B2024-12-31: £1.10B2025-12-31: £822.55M£1.94B£0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in GBP. Dates are period ends; a fiscal year may differ from a calendar year.

PSO other current assets history

Current assets not classified elsewhere. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Pearson, Plc Common Stock Other Current Assets — Annual fiscal periods (GBP)
Period endingOther Current Assets (GBP)
822,551,663
1,100,000,000
1,199,000,000
1,299,000,000
1,304,000,000
1,289,000,000
1,434,000,000
1,768,000,000
1,871,000,000
1,420,000,000
1,219,000,000
1,191,000,000
1,263,000,000
1,939,000,000
847,000,000
835,000,000
824,000,000
868,000,000
1,514,262,750
1,355,138,550
1,456,386,960
1,267,426,160
1,275,680,000
1,231,145,550
1,280,107,800
12,051,360
1,134,323,600
1,127,000,000
807,000,000
53,500,000
61,200,000
43,500,000
35,500,000
42,900,000
24,500,000
0
0
0
0
0
0

Compare other current assets

All PSO financial metrics · PSO stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.